<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Ophthalmic</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Alcon wishes on the wrong Staar as $1.6B merger rejected</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[It appears that Staar Surgical Co.'s proposed $1.6 billion merger with Alcon AG has been scrapped as Staar shareholders voted against the deal in a stockholder meeting on Jan. 6. In a statement Staar said it intends to terminate its merger agreement with Alcon. No termination fee will be payable by either party, and Staar will remain a stand-alone, publicly traded company.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727575</guid>
      <pubDate>Tue, 06 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727575-alcon-wishes-on-the-wrong-staar-as-16b-merger-rejected</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/deal-merger-acquisition-cancel-terminate.webp?t=1588276898" type="image/png" medium="image" fileSize="211268">
        <media:title type="plain">Hands holding torn contract</media:title>
      </media:content>
    </item>
    <item>
      <title>Alcon reports strong 3Q, unsure about Staar merger</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Alcon AG reported its financial results for the three- and nine-month periods ending Sept. 30, 2025. For the third quarter of 2025, sales were $2.6 billion, up 6% on a reported basis and up 5% on a constant currency basis, as compared to the same quarter of the previous year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725980</guid>
      <pubDate>Thu, 13 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725980-alcon-reports-strong-3q-unsure-about-staar-merger</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Businessperson-completing-checklist.webp?t=1738778263" type="image/jpeg" medium="image" fileSize="115231">
        <media:title type="plain">Businessperson completing checklist</media:title>
      </media:content>
    </item>
    <item>
      <title>Staar adjourns Alcon merger meeting until November</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Staar Surgical Co. reported on Oct. 24 that it had adjourned its special meeting of stockholders scheduled in connection with its proposed $1.5 billion sale to Alcon AG in the face of objections from some of its major shareholders and at least three proxy firms.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725172</guid>
      <pubDate>Fri, 24 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725172-staar-adjourns-alcon-merger-meeting-until-november</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Broken-contract.webp?t=1675372768" type="image/png" medium="image" fileSize="230802">
        <media:title type="plain">Pen and ripped contract</media:title>
      </media:content>
    </item>
    <item>
      <title>Science Corp.'s Prima implant enables blind patients to read</title>
      <description>
        <![CDATA[Interim results from the PRIMAVERA study published in the <em>New England Journal of Medicine</em> demonstrated that Science Corp.'s Prima retinal implant restored vision, enabling 80% of patients to read at 12 months. Participants had age-related macular degeneration-related geographic atrophy resulting in total loss of central vision.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725154</guid>
      <pubDate>Wed, 22 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725154-science-corps-prima-implant-enables-blind-patients-to-read</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/PRIMA-22oct24.webp?t=1772740430" type="image/jpeg" medium="image" fileSize="353671">
        <media:title type="plain">PRIMA implant</media:title>
        <media:description type="plain">Prima implant. Credit: Science Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Staar sale to Alcon eclipsed by shareholder, proxy advisor concerns</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[ISS became the third proxy advisory firm to recommend shareholders vote against the proposed sale of Staar Surgical Co. to Alcon AG, joining Glass, Lewis & Co. LLC and Egan-Jones Ratings Co. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/724938</guid>
      <pubDate>Thu, 16 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724938-staar-sale-to-alcon-eclipsed-by-shareholder-proxy-advisor-concerns</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Stock-prices-with-loss-and-gain-arrows.webp?t=1622663121" type="image/png" medium="image" fileSize="519113">
        <media:title type="plain">Stock prices with loss/gain arrows</media:title>
      </media:content>
    </item>
    <item>
      <title>Opzira launches with former Lumithera diagnostics</title>
      <description>
        <![CDATA[You can’t fault Alcon AG’s focus. In the midst of an extended series of acquisitions, the company has a clear vision of creating a deep ophthalmic treatment pipeline – and diagnostics fall outside that line of sight.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723573</guid>
      <pubDate>Thu, 04 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723573-opzira-launches-with-former-lumithera-diagnostics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Acquisition-puzzle.webp?t=1682968589" type="image/jpeg" medium="image" fileSize="193595">
        <media:title type="plain">Acquisition puzzle</media:title>
      </media:content>
    </item>
    <item>
      <title>Ciliatech receives CE mark for glaucoma implant</title>
      <description>
        <![CDATA[Ciliatech SAS received CE certification under the Medical Device Regulation for its Intercil Uveal Spacer, a surgical implant developed to treat glaucoma. The cilio-scleral inter-positioning device lowers intraocular pressure without penetrating the anterior chamber, marking the arrival of a new treatment option for glaucoma patients.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723440</guid>
      <pubDate>Wed, 27 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723440-ciliatech-receives-ce-mark-for-glaucoma-implant</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Ciliatech-Intercil-Uveal-Spacer-27aug25.webp?t=1756329542" type="image/jpeg" medium="image" fileSize="111961">
        <media:title type="plain">Ciliatech Intercil Uveal Spacer</media:title>
        <media:description type="plain">Ciliatech's Intercil uveal spacer. Credit: Ciliatech.</media:description>
      </media:content>
    </item>
    <item>
      <title>Iantrek raises $42M for Alloflo Uveo glaucoma therapy launch</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Iantrek Inc. reported the close of a $42 million series C financing round, which it said will facilitate the U.S. commercial launch of its Alloflo Uveo, a bio-interventional ophthalmic surgery solution targeting the lightly used uveoscleral pathway, as well as broader pipeline expansion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723439</guid>
      <pubDate>Wed, 27 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723439-iantrek-raises-42m-for-alloflo-uveo-glaucoma-therapy-launch</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Iantrek-alloflo-uveo-27aug25.webp?t=1756331032" type="image/jpeg" medium="image" fileSize="113012">
        <media:title type="plain">Iantrek Alloflo Uveo</media:title>
        <media:description type="plain">Iantrek Alloflo Uveo. Credit: Iantrek</media:description>
      </media:content>
    </item>
    <item>
      <title>Bright move: Alcon offers $1.5B for Staar Surgical</title>
      <description>
        <![CDATA[Alcon AG agreed to acquire Staar Surgical Co. in a $1.5 billion cash transaction that would add Staar’s Evo implantable Collamer lenses (ICL) to treat myopia to the vision giant’s portfolio. Alcon will pay $28 per share, a 59% premium on Staar’s 90-day volume-weighted average price and a 51% premium on the Aug. 4 closing price of its shares (Nasdaq: STAA). ]]>
      </description>
      <guid>http://www.bioworld.com/articles/722654</guid>
      <pubDate>Tue, 05 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722654-bright-move-alcon-offers-15b-for-staar-surgical</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Acquisition-puzzle.webp?t=1682968589" type="image/jpeg" medium="image" fileSize="193595">
        <media:title type="plain">Acquisition puzzle</media:title>
      </media:content>
    </item>
    <item>
      <title>Alcon sees the light with Lumithera buy for dry AMD</title>
      <description>
        <![CDATA[<a href="https://www.bioworld.com/keywords/23638-alcon-ag">Alcon AG</a> plans to acquire <a href="https://www.bioworld.com/articles/516676-lumithera-eyes-global-ocular-disease-market-in-diopsys-deal">Lumithera Inc.</a>, adding its photobiomodulation (PBM) device designed to treat early and intermediate dry age-related macular degeneration (AMD) to the Alcon portfolio. The financial terms of the deal were not disclosed.
The move continues Alcon’s strategic expansion in eye care, following on its recent acquisitions of <a href="https://www.cortellis.com/intelligence/qsearch/%22aurion%20biotech%20inc%22?indexBased=true&searchCategory=ALL" target="_blank">Aurion Biotech Inc.</a> and <a href="https://www.cortellis.com/intelligence/qsearch/%22lensar%20inc%22?indexBased=true&searchCategory=ALL" target="_blank">Lensar Inc.</a>]]>
      </description>
      <guid>http://www.bioworld.com/articles/721808</guid>
      <pubDate>Wed, 09 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721808-alcon-sees-the-light-with-lumithera-buy-for-dry-amd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Close-up-of-eye-and-vision-test.webp?t=1730493501" type="image/jpeg" medium="image" fileSize="159676">
        <media:title type="plain">Close up of eye and vision test</media:title>
      </media:content>
    </item>
    <item>
      <title>Polyactiva raises $25M series C to advance U.S. clinical programs</title>
      <description>
        <![CDATA[Ophthalmology company Polyactiva Pty Ltd closed a AU$40 million (US$25 million) series C round to advance late-stage clinical trials in the U.S. of its lead candidate, PA-5108.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721833</guid>
      <pubDate>Tue, 01 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721833-polyactiva-raises-25m-series-c-to-advance-us-clinical-programs</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Polyactiva-implant-25june25.webp?t=1750886384" type="image/jpeg" medium="image" fileSize="463813">
        <media:title type="plain">Polyactiva implant</media:title>
        <media:description type="plain">Polyactiva’s ocular implants are two millimeters long and .2 mm in diameter. Credit: Polyactiva</media:description>
      </media:content>
    </item>
    <item>
      <title>Forsight Robotics secures $125M for eye surgery robotics platform</title>
      <description>
        <![CDATA[Forsight Robotics Ltd. secured $125 million in series B financing for its Oryom platform, a robotic system for cataract surgery.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721248</guid>
      <pubDate>Fri, 27 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721248-forsight-robotics-secures-125m-for-eye-surgery-robotics-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Close-up-of-eye-and-vision-test.webp?t=1730493501" type="image/jpeg" medium="image" fileSize="159676">
        <media:title type="plain">Close up of eye and vision test</media:title>
      </media:content>
    </item>
    <item>
      <title>Polyactiva raises $25M series C to advance U.S. clinical programs</title>
      <description>
        <![CDATA[Ophthalmology company Polyactiva Pty Ltd closed a AU$40 million (US$25 million) series C round to advance late-stage clinical trials in the U.S. of its lead candidate, PA-5108.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721713</guid>
      <pubDate>Wed, 25 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721713-polyactiva-raises-25m-series-c-to-advance-us-clinical-programs</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Polyactiva-implant-25june25.webp?t=1750886384" type="image/jpeg" medium="image" fileSize="463813">
        <media:title type="plain">Polyactiva implant</media:title>
        <media:description type="plain">Polyactiva’s ocular implants are two millimeters long and .2 mm in diameter. Credit: Polyactiva</media:description>
      </media:content>
    </item>
    <item>
      <title>Series B brings Splicebio $135M for Stargardt disease asset</title>
      <description>
        <![CDATA[Three months after dosing the first patient with its dual vector gene therapy, Splicebio SL has closed a $135 million series B to fund the phase I/II trial of SB-007 in the treatment of Stargardt’s disease to completion. Other adeno-associated viru gene therapies for the inherited retinal disorder have entered the clinic, but SB-007 is the first with the capacity to deliver a full version of the ABCA4 gene that underlies Stargardt’s.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721016</guid>
      <pubDate>Wed, 11 Jun 2025 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721016-series-b-brings-splicebio-135m-for-stargardt-disease-asset</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gold-dollar-sign.webp?t=1592343941" type="image/png" medium="image" fileSize="265558">
        <media:title type="plain">Gold dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Alcon to acquire Lensar for up to $430M</title>
      <description>
        <![CDATA[Alcon AG plans to acquire Lensar Inc. for up to $430 million in a transaction expected to close in the latter half of the year. The acquisition will add Lensar’s Ally robotic cataract laser treatment system, Streamline software technology and Lensar legacy laser system to Alcon’s cataract surgery portfolio and expand global access to Lensar’s femtosecond laser technology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718199</guid>
      <pubDate>Mon, 24 Mar 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718199-alcon-to-acquire-lensar-for-up-to-430m</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-between-hands.webp?t=1740610521" type="image/jpeg" medium="image" fileSize="123345">
        <media:title type="plain">Dollar sign between hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Roche, University of Liverpool set sights on eye cancer</title>
      <description>
        <![CDATA[Roche Holding AG and the University of Liverpool in the U.K. launched an initiative to improve the early detection of rare eye cancers with the help of the Ventana DP 600 digital pathology slide scanner.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718197</guid>
      <pubDate>Mon, 24 Mar 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718197-roche-university-of-liverpool-set-sights-on-eye-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Roche-Ventana-DP-600-24mar25.webp?t=1742851196" type="image/jpeg" medium="image" fileSize="240269">
        <media:title type="plain">Roche Ventana DP600</media:title>
        <media:description type="plain">Roche Ventana DP600 digital pathology slide scanner. Credit: Roche Holding AG</media:description>
      </media:content>
    </item>
    <item>
      <title>Researchers develop visual prosthetic to restore sight</title>
      <description>
        <![CDATA[Researchers from the Albert Einstein College of Medicine filed for protection of the development of a lateral geniculate nucleus (LGN) visual prosthetic device with implantable electrode arrays that stimulate the LGN and restore vision.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718006</guid>
      <pubDate>Fri, 21 Mar 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718006-researchers-develop-visual-prosthetic-to-restore-sight</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Patent Highlights/Implantable-electrode-assemblies-3-20.webp?t=1742593582" type="image/jpeg" medium="image" fileSize="136221">
        <media:title type="plain">Implantable electrode assemblies</media:title>
        <media:description type="plain">WO2025049400-A1, “Implantable electrode assemblies, including implantable electrode assemblies for the brain, and associated systems, devices, and methods.”Assignee: Albert Einstein College of Medicine; Raven Neuro Inc.

Inventors: Eskandar, Emad; Killian, Nathaniel; Shank, AaronIPC codes: A61B 18/14; A61N 1/05; A61N 1/36

Publication date: March 6, 2025Earliest priority details: US2023578718, Aug. 25, 2023</media:description>
      </media:content>
    </item>
    <item>
      <title>Verily developing vaporized ophthalmic drug delivery device</title>
      <description>
        <![CDATA[A recent patent filing from Verily Life Sciences LLC seeks protection for the development of an ophthalmic drug delivery device with sensors and a camera which allow the delivery of a specific or controlled dose of a therapeutic agent in vapor form to a patient’s eye.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717629</guid>
      <pubDate>Fri, 28 Feb 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717629-verily-developing-vaporized-ophthalmic-drug-delivery-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/vaporized-ophthalmic-drug-delivery-28feb25.webp?t=1740785338" type="image/jpeg" medium="image" fileSize="193391">
        <media:title type="plain">vaporized ophthalmic drug delivery</media:title>
        <media:description type="plain">WO2025038348-A1, “Vaporized ophthalmic drug delivery device.”Assignee: Verily Life Sciences LLCInventors: Armstrong, Maxim; McGuire, AllisterIPC dodes: A61F 9/007; A61F 9/00Publication date: Feb. 20, 2025Earliest priority details: US2023532081, Aug. 11, 2023</media:description>
      </media:content>
    </item>
    <item>
      <title>Seonix Bio sees future in genetic test for glaucoma</title>
      <description>
        <![CDATA[Up to 50% of glaucoma cases have a genetic component, a factor which could significantly change the screening recommendations and monitoring of patients – if they know their risk. Seonix Pty. Ltd. has a vision for making that genetic information easier to obtain and use to guide care with its Sightscore saliva-based test.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717171</guid>
      <pubDate>Thu, 20 Feb 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717171-seonix-bio-sees-future-in-genetic-test-for-glaucoma</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Polygenic_risk_score_graphic_20feb25.webp?t=1740091720" type="image/jpeg" medium="image" fileSize="267888">
        <media:title type="plain">Polygenic risk score</media:title>
      </media:content>
    </item>
    <item>
      <title>Essilorluxottica receives US, EU, green light for OTC Audio Glasses</title>
      <description>
        <![CDATA[Essilorluxottica SA received U.S. FDA clearance for its over-the-counter Nuance Audio Glasses, which combines sight and sound technologies, to help people improve their vision and hearing. The device also received a CE mark certification under the Medical Devices Regulation from the EU authorities.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716792</guid>
      <pubDate>Mon, 03 Feb 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716792-essilorluxottica-receives-us-eu-green-light-for-otc-audio-glasses</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/ENT/Hearing-loss-illustration.webp?t=1738616487" type="image/jpeg" medium="image" fileSize="191144">
        <media:title type="plain">Hand cupping ear to illustration hearing loss</media:title>
      </media:content>
    </item>
    <item>
      <title>‘Little giant’ Eyebright’s phakic IOL cleared for myopia in China</title>
      <description>
        <![CDATA[Eyebright Medical Technology (Beijing) Co. Ltd. is expanding its position in China’s phakic intraocular lens (IOL) market, gaining the National Medical Products Administration (NMPA) approval of its Loong Crystal PR phakic IOL product for myopia in adults in January 2025.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716470</guid>
      <pubDate>Thu, 30 Jan 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716470-little-giant-eyebrights-phakic-iol-cleared-for-myopia-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Eyebright-MeiyueTongTOPPOP-Smart-store-24jan25pg.webp?t=1738274612" type="image/jpeg" medium="image" fileSize="245401">
        <media:title type="plain">Eyebright Meiyue Tong TOPPOP Smart store</media:title>
      </media:content>
    </item>
    <item>
      <title>Eyecheq files for protection of self-service retinal image kiosks</title>
      <description>
        <![CDATA[In what represents the first patenting from Eyecheq Inc., the company is seeking protection for its self-guided eye examination systems which may be mounted in easily movable and transportable kiosks, on tabletop stands, walls or suspended from ceilings.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713770</guid>
      <pubDate>Thu, 31 Oct 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713770-eyecheq-files-for-protection-of-self-service-retinal-image-kiosks</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Patent Highlights/self-eye-exam-31oct24.webp?t=1730411339" type="image/png" medium="image" fileSize="53382">
        <media:title type="plain">self-eye-exam-31oct24.png</media:title>
        <media:description type="plain">WO2024215926-A1, “Self-guided eye examination system.”Assignee: Eyecheq Inc.Inventors: Khoshnevis, Ali; Taher, Rashid; Barber, James E.; Boll, David J.; Pehar, David Michael; Sords, Peter R.; Vystrcil, Robert; Zimmerman, SloanIPC codes: A61B 3/14; A61B 3/032; A61B 3/10; A61B 3/103; A61B 3/00; A61B 3/12Publication date: Oct. 17, 2024 (also published as US20240341586-A1)Earliest priority details: US2023298557, Apr. 11, 2023</media:description>
      </media:content>
    </item>
    <item>
      <title>Nu Eyne advances bioelectric wearables beyond migraine, ADHD</title>
      <description>
        <![CDATA[Beyond its success in migraine and attention deficit hyperactivity disorder, Nu Eyne Co. Ltd. is advancing a portfolio of noninvasive, wearable trigeminal nerve stimulation devices across key three areas of neuromodulation, tissue regeneration and proliferation inhibition.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710305</guid>
      <pubDate>Wed, 17 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710305-nu-eyne-advances-bioelectric-wearables-beyond-migraine-adhd</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Addnox-by-Nu-Eyne-7-17.webp?t=1721247349" type="image/jpeg" medium="image" fileSize="86727">
        <media:title type="plain">Addnox migraine device by Nu Eyne</media:title>
        <media:description type="plain">Nu Eyne's device for ADHD, currently called Smile. The company plans to change the product’s name to Addnox and launch in the U.S. in the first half of 2025.</media:description>
      </media:content>
    </item>
    <item>
      <title>Alcon buys Belkin Vision for up to $466M</title>
      <description>
        <![CDATA[Alcon AG completed the acquisition of Belkin Vision Ltd. with an upfront consideration of $81 million with an additional $385 million in contingent payments. With the deal, Alcon gets its hands on Belkin’s U.S. FDA-cleared direct selective laser trabeculoplasty device, expanding its treatment options for patients with glaucoma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709776</guid>
      <pubDate>Tue, 02 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709776-alcon-buys-belkin-vision-for-up-to-466m</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Belkin-DSLT-device-2july24.webp?t=1719959722" type="image/jpeg" medium="image" fileSize="107212">
        <media:title type="plain">Belkin DSLT device</media:title>
        <media:description type="plain">Belkin DSLT device. Credit: Belkin Vision</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA moves to down-classify cyclodestruction in glaucoma</title>
      <description>
        <![CDATA[Ultrasound cyclodestruction may not be the darling of American ophthalmologists and their patients dealing with glaucoma, but that may soon change thanks to a recent move by the U.S. FDA. The agency has down-classified these devices from class III to class II in a move that may prompt competition for current device-based methods of treating glaucoma, including widely used laser-based treatments.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708553</guid>
      <pubDate>Mon, 20 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708553-fda-moves-to-down-classify-cyclodestruction-in-glaucoma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Laptop-displaying-FDA-logo.webp?t=1695241730" type="image/png" medium="image" fileSize="347445">
        <media:title type="plain">Laptop displaying FDA logo</media:title>
      </media:content>
    </item>
    <item>
      <title>China approves Arcscan’s ultrasound imaging device for myopia</title>
      <description>
        <![CDATA[Denver-based Arcscan Inc. gained Chinese approval of its computer-controlled, ultra-high frequency ultrasound diagnostic imaging solution for myopia called Insight 100, expanding its reach beyond the U.S. and Europe.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708283</guid>
      <pubDate>Fri, 17 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708283-china-approves-arcscans-ultrasound-imaging-device-for-myopia</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Arcscan-17may24.webp?t=1715980775" type="image/jpeg" medium="image" fileSize="69004">
        <media:title type="plain">Arcscan</media:title>
        <media:description type="plain">Arcscan computer-controlled, ultra-high frequency ultrasound diagnostic imaging. Credit: Arcscan Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>J&amp;J’s Duato says company to continue M&amp;A surge</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[As Johnson & Johnson's (J&J) first-quarter revenue missed Wall Street estimates for medical devices on April 16, CEO Joaquin Duato noted that the company will continue to look for major M&A plays to boost long-term growth in the wake of its recently reported $13.1 billion buy of Shockwave Medical Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/707443</guid>
      <pubDate>Wed, 17 Apr 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/707443-j-and-js-duato-says-company-to-continue-m-and-a-surge</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Global-deal-merger.webp?t=1588276766" type="image/png" medium="image" fileSize="334962">
        <media:title type="plain">Business people with hands atop a digital globe</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA advisory panel sees benefit in ocular negative pressure therapy</title>
      <description>
        <![CDATA[The notion of using vacuum pressure on the anterior portion of the human eye as a treatment for open-angle glaucoma might be a clinical novelty, but Balance Ophthalmics Inc. is poised to change that. The company recently won a favorable outcome at a U.S. FDA advisory panel for its Fsyx negative pressure pump for ocular use, although the company is likely to have to drum up a large body of data in post-approval studies, assuming the FDA gives the Fsyx the nod.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706890</guid>
      <pubDate>Mon, 01 Apr 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/706890-fda-advisory-panel-sees-benefit-in-ocular-negative-pressure-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/AMD-macular-degeneration.webp?t=1685025496" type="image/jpeg" medium="image" fileSize="112128">
        <media:title type="plain">Illustration of the inside of an eye with macular degeneration</media:title>
      </media:content>
    </item>
    <item>
      <title>US court sees fines levied on Precision Lens as unconstitutional</title>
      <description>
        <![CDATA[The U.S. Department of Justice (DOJ) announced in May 2023 that it had obtained a judgment of more than $487 million against the parent company of Precision Lens for alleged violations of the False Claims Act (FCA), but the amount of that decision has been overturned. In a Feb. 8 decision, the U.S. District Court for the District of Minnesota decreed that the judgment be reduced to less than $217 million, an outcome which suggests that some of the more excessive fines levied against health care companies will be viewed with more skepticism upon appeal.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705435</guid>
      <pubDate>Tue, 20 Feb 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705435-us-court-sees-fines-levied-on-precision-lens-as-unconstitutional</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Courts2.webp?t=1588285720" type="image/png" medium="image" fileSize="600807">
        <media:title type="plain">Architectural pillars</media:title>
      </media:content>
    </item>
    <item>
      <title>Spyglass strengthens IP for intraocular drug delivery platform</title>
      <description>
        <![CDATA[Spyglass Ophthalmics Inc. is seeking patent protection for intraocular drug delivery devices and methods of delivering therapeutic agents to the eye. The methods include implanting an intraocular implant into the eye and adjacent to a fluid-permeable membrane of the patient’s eye.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705068</guid>
      <pubDate>Wed, 07 Feb 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705068-spyglass-strengthens-ip-for-intraocular-drug-delivery-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Patent Highlights/spyglass-intraocular-drug-delivery-6feb24.webp?t=1707343070" type="image/jpeg" medium="image" fileSize="87700">
        <media:title type="plain">Spyglass intraocular drug delivery</media:title>
        <media:description type="plain">WO2024020505-A2, “Intraocular drug delivery systems and methods of use.”Assignee: Spyglass Ophthalmics Inc.; University of Colorado SystemInventors: Absalonson, Ryan; Cable, II, Craig Alan; Kahook, Malik Y.; Sussman, Glenn R.IPC Codes: A61F 2/16; A61F 9/00; A61K 47/59; A61K 9/70Publication date: Jan. 25, 2024 (shares priority details with co-published US20240024092, ‘093, and ‘158-A1)Earliest priority details: US2022391399, July 22, 2022</media:description>
      </media:content>
    </item>
  </channel>
</rss>
